The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Phase II study of everolimus in metastatic urothelial cancer
Open accessAbstract
What's known on the subject? and What does the study add?: No recent advances have been made in the treatment of patients with advanced bladder cancer and, to date, targeted therapies have not resulted in an improvement in outcome. The mammalian target of rapamycin pathway has been shown to be up‐regulated in bladder cancer and represents a rational target for therapeutic intervention. In the present phase II study of everolimus, one near‐complete response, one partial response and several minor responses suggest that everolimus possesses biological activity in a subset of patients with bladder cancer. To maximize benefit from targeted agents such as everolimus, the preselection of patients based on molecular phenotype is required. Objective: To assess the efficacy and tolerability of everolimus in advanced urothelial carcimoma ( UC ). Patients and Methods: The present study comprised a single‐arm, non‐randomized study in which all patients received everolimus 10 mg orally once daily continuously (one cycle = 4 weeks). In total, 45 patients with metastatic UC progressing after one to four cytotoxic agents were enrolled between F ebruary 2009 and N ovember 2010 at the M emorial S loan‐ K ettering C ancer C enter. The primary endpoints were 2‐month progression‐free survival ( PFS ) and the safety of everolimus, with the secondary endpoint being the response rate. A S imon minimax two‐stage design tested the null hypothesis that the true two month PFS rate was ≤50%, as opposed to the alternative hypothesis of ≥70%. Results: The most common grade 3/4 toxicities were fatigue, infection, anaemia, lymphopaenia, hyperglycaemia and hypophosphataemia. There were two partial responses in nodal metastases, with one patient achieving a 94% decrease in target lesions and remaining on drug at 26 months. An additional 12 patients exhibited minor tumour regression. There were 23 of 45 (51%) patients who were progression‐free at 2 months with a median (95% CI ) PFS of 2.6 (1.8–3.5) months and a median (95% CI ) overall survival of 8.3 (5.5–12.1) months. No clear association was observed between mammalian target of rapamycin pathway marker expression and 2‐month PFS . Conclusions: Although everolimus did not meet its primary endpoint, one partial response, one near‐complete response and twelve minor regressions were observed. Everolimus possesses meaningful anti‐tumour activity in a subset of patients with advanced UC . Studies aiming to define the genetic basis of everolimus activity in individual responders are ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
Cited by
Metabolic phenotype of bladder cancer
Massari, F., Ciccarese, C., Santoni, M., Iacovelli, R., Mazzucchelli, R., Piva, F., Scarpelli, M., Berardi, R., Tortora, G., Lopez-Beltran, A., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.005 · Cited by 334
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
Mamtani, R., Pfanzelter, N., Haynes, K., Finkelman, B. S., Wang, X., Keefe, S. M., Haas, N. B., Vaughn, D. J., & Lewis, J. D. (2014) · Diabetes Care · doi:10.2337/dc13-1489 · Cited by 71
Metadata
- Authors
- Milowsky, M. I., Iyer, G., Regazzi, A. M., Al‐Ahmadie, H., Gerst, S. R., Ostrovnaya, I., Gellert, L. L., Kaplan, R., Garcia‐Grossman, I. R., Pendse, D., Balar, A. V., Flaherty, A. M., Trout, A., Solit, D. B., & Bajorin, D. F.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2013-04-03
- Volume
- 112
- Issue
- 4
- Pages
- 462-470
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W1725351598
- Cited by
- 166
- References
- 3
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II study of everolimus in metastatic urothelial cancer. https://app.cochat.ai/papers/10.1111/j.1464-410x.2012.11720.x
- The paper
- Milowsky, M. I., Iyer, G., Regazzi, A. M., Al‐Ahmadie, H., Gerst, S. R., Ostrovnaya, I., Gellert, L. L., Kaplan, R., Garcia‐Grossman, I. R., Pendse, D., Balar, A. V., Flaherty, A. M., Trout, A., Solit, D. B., & Bajorin, D. F. (2013). Phase II study of everolimus in metastatic urothelial cancer. BJU International. https://doi.org/10.1111/j.1464-410x.2012.11720.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.